In brief: The research article presents a novel TCL1–BCL2–driven mouse model, while the review advances our understanding of BCL2‑inhibitor resistance in chronic lymphocytic leukaemia (CLL). Both publications are the result of strong collaborative efforts within the SFB 1530 | CRC 1530 and with partners beyond.
Read the articles:
1. Halmer I., et al. & Frenzel, L.P. Eμ-TCL1 mice with conditional human BCL2 knock-in as novel B cell lymphoma model for studying venetoclax effects in vivo. blood neoplasia (2025). https://doi.org/10.1016/j.bneo.2025.100143
2. vom Stein, A. & Frenzel, L.P. Understanding and Targeting BCL2-inhibitor Resistance in Chronic Lymphocytic Leukemia. Hematology/Oncology Clinics of North America (2025). https://doi.org/10.1016/j.hoc.2025.06.001
